CVS Health (NYSE:CVS) Announces Earnings Results, Beats Expectations By $0.71 EPS

CVS Health (NYSE:CVS) posted its earnings results on Wednesday. The pharmacy operator reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71, FiscalAI reports. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter in the prior year, the company posted $1.81 earnings per share. CVS Health’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health updated its FY 2026 guidance to 7.900-8.100 EPS.

Here are the key takeaways from CVS Health’s conference call:

• CVS raised its 2026 outlook after a strong quarter, increasing adjusted EPS guidance by $0.60 to $7.90–$8.10 and raising operating cash-flow expectations to at least $11.5 billion.
• Second-quarter performance was broad-based: revenue rose more than 7% to over $106 billion, adjusted operating income increased 35% to approximately $5.2 billion, and adjusted EPS grew over 40% to $2.58. All operating segments reported year-over-year earnings growth.
• Aetna’s margin recovery is progressing faster than expected, with more than $2 billion of year-to-date adjusted operating-income improvement; management cited disciplined pricing, medical-cost management, and favorable Medicare performance.
• Management sees growing opportunities in GLP-1s through formulary management, cash-pay offerings, MinuteClinic weight-management visits, and manufacturer partnerships with Lilly and Novo. The company plans to reduce the virtual weight-management visit price to $29 and expand same-day pharmacy access.
• CVS expects 2027 headwinds from continued pressure in its 340B business and lower Caremark membership, partly due to more selective contracting and health-plan product exits. Management said these pressures should be offset over time by specialty pharmacy growth, generic savings, and broader enterprise momentum.

CVS Health Stock Performance

Shares of CVS stock opened at $99.24 on Thursday. The business has a fifty day moving average of $102.10 and a 200 day moving average of $87.56. CVS Health has a 1 year low of $62.52 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $126.62 billion, a price-to-earnings ratio of 43.72, a price-to-earnings-growth ratio of 1.02 and a beta of 0.61.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Insider Activity

In related news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Company insiders own 0.85% of the company’s stock.

Institutional Trading of CVS Health

Large investors have recently made changes to their positions in the business. State Street Corp lifted its position in CVS Health by 0.3% during the third quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock valued at $4,443,357,000 after purchasing an additional 149,701 shares during the period. Morgan Stanley lifted its holdings in CVS Health by 6.3% in the fourth quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock valued at $1,616,863,000 after acquiring an additional 1,211,631 shares during the period. Wellington Management Group LLP lifted its holdings in CVS Health by 193.2% in the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after acquiring an additional 12,233,675 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in CVS Health by 4.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 8,312,341 shares of the pharmacy operator’s stock worth $659,667,000 after purchasing an additional 387,467 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of CVS Health by 5.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 7,855,845 shares of the pharmacy operator’s stock worth $541,903,000 after purchasing an additional 385,806 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Major earnings and revenue beat: Adjusted EPS rose to $2.58 from $1.81 a year earlier, exceeding the $1.87 consensus estimate. Revenue increased 7.3% to $106.1 billion, above expectations near $100 billion. All three major segments—Aetna, pharmacy and health services—outperformed revenue estimates. CNBC CVS earnings report
• Positive Sentiment: Guidance and cash flow raised: CVS lifted its 2026 adjusted EPS outlook to $7.90–$8.10 from $7.30–$7.50, above the roughly $7.44 analyst consensus. GAAP EPS guidance also increased to $6.84–$7.04, while operating cash flow guidance rose to at least $11.5 billion from $9.5 billion. CVS Health second-quarter results
• Positive Sentiment: Aetna improvement drove profitability: Lower-than-expected medical costs, government-plan bonus payments and a more favorable pharmacy drug mix helped produce nearly $3 billion in quarterly profit, signaling progress in CVS’s insurance turnaround. Reuters CVS profit forecast report
• Positive Sentiment: GLP-1 opportunity expanded: CVS announced a collaboration with Eli Lilly to improve access to Zepbound and other weight-management treatments. Its offering includes $29 MinuteClinic digital visits, cash-pay and insurance options, same-day pharmacy pickup and pharmacist support, potentially strengthening customer engagement and future revenue opportunities. CVS Health GLP-1 offering
• Neutral Sentiment: Mixed trading reaction: Despite the earnings beat and raised outlook, reports said CVS shares reversed early gains after management remarks concerning the PBM unit. Investors may be seeking clearer evidence that Caremark’s performance and longer-term margins can improve alongside Aetna. Seeking Alpha CVS PBM reaction

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CVS shares. Argus increased their price objective on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. DA Davidson upped their target price on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Truist Financial increased their price target on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Barclays reissued an “overweight” rating on shares of CVS Health in a report on Thursday. Finally, Cantor Fitzgerald boosted their price target on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $105.67.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.